AMGN ▼ -1.5% - Amgen Inc. $AMGN AMGN - AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE Amgen shares fell 1.5% today despite positive news from a late-stage trial showing that its drug Repatha® reduced the risk of death in high-risk cardiovascular patients. While the trial result represents a significant clinical achievement, investors may have already priced in expectations for the drug, or the market could be focused on other near-term factors affecting the stock. 31-AUG-2026 03:19 AM ET